Multiple Sclerosis Journal - Experimental, Translational and Clinical最新文献_第4页

Qualitative user experience evaluation of the MS trust's online treatment decision aid tool's accommodation of planning pregnancy. 对多发性硬化症信托基金在线治疗决策辅助工具为计划怀孕提供便利的用户体验进行定性评估。

IF 2.8

Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2024-06-11 eCollection Date: 2024-04-01 DOI: 10.1177/20552173241262181

Lubna Almouzain, Fiona L Hamilton, Declan Chard, Fiona Stevenson

{"title":"Qualitative user experience evaluation of the MS trust's online treatment decision aid tool's accommodation of planning pregnancy.","authors":"Lubna Almouzain, Fiona L Hamilton, Declan Chard, Fiona Stevenson","doi":"10.1177/20552173241262181","DOIUrl":"10.1177/20552173241262181","url":null,"abstract":"Background: Decision-making about treatment when planning a pregnancy (family planning) is complex for women living with multiple sclerosis (MS). Decision tools can help this process, in 2016 MS Trust launched their online digital treatment decision tool to support people with MS.Objectives: To evaluate user-experience of this tool by exploring women's opinions about its content, interface, and usefulness in the context of family planning; and to synthesize recommendations to improve the tool.Methods: Thirty participants qualitatively evaluated the tool using Think Aloud methodology. Sessions were conducted online using Microsoft Teams and were video recorded. Transcription was automated and data were thematically analyzed.Results: Women's first impression was that the tool presented a lot of information at once, which was difficult to take in, and they found it difficult to navigate. Although the tool was helpful in allowing them to compare treatment options, the filters were confusing, and the information related to pregnancy sometimes contradicted advice from their healthcare practitioners. They suggested rewording the pregnancy recommendations and filters, updating some content, and making some changes to the interface to meet users' cognitive needs.Conclusion: The MS Trust treatment decision tool is excellent in helping women with treatment choices at initial diagnosis. However, it is not currently as useful when considering family plans. Recommendations were conveyed to MS Trust where some are now applied to the new live version and the rest are to be considered for future updating projects.","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"10 2","pages":"20552173241262181"},"PeriodicalIF":2.8,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11171435/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141317840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Abnormal eye movements increase as motor disabilities and cognitive impairments become more evident in Multiple Sclerosis: A novel eye-tracking study. 随着多发性硬化症患者的运动障碍和认知障碍日益明显，异常眼球运动也随之增加：一项新颖的眼动追踪研究

IF 2.8

Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2024-05-29 eCollection Date: 2024-04-01 DOI: 10.1177/20552173241255008

Fernández Gerardo, Eizaguirre Bárbara, Gonzalez Cecilia, Marinangeli Aldana, Ciufia Natalia, Bacigalupe Lucia, Berenice Silva, Cohen Leila, Pita Cecilia, Garcea Orlando, Casas Magdalena, Lazaro Luciana, Pardo Gabriel, Alonso Ricardo

{"title":"Abnormal eye movements increase as motor disabilities and cognitive impairments become more evident in Multiple Sclerosis: A novel eye-tracking study.","authors":"Fernández Gerardo, Eizaguirre Bárbara, Gonzalez Cecilia, Marinangeli Aldana, Ciufia Natalia, Bacigalupe Lucia, Berenice Silva, Cohen Leila, Pita Cecilia, Garcea Orlando, Casas Magdalena, Lazaro Luciana, Pardo Gabriel, Alonso Ricardo","doi":"10.1177/20552173241255008","DOIUrl":"10.1177/20552173241255008","url":null,"abstract":"Background: Eye movements can reflect brain alterations and inform on the presence of motor disabilities and cognitive impairments in people with multiple sclerosis (pwMS).Objective: The aim of the study was to determine the correlation between motor and cognitive measurements and eye movement parameters when performing the n-back task (NBKT).Methods: This was a cross-sectional study carried out at Ramos Mejía Hospital, a center specialized in demyelinating diseases in Buenos Aires, Argentina. The study population consisted of 66 patients with relapsing-remitting multiple sclerosis (RRMS) and 5 patients with secondary progressive multiple sclerosis (SPMS). pwMS performed the n-back test while using a device head mounted display (HMD) with eyetracking capabilities in order to capture eye movement. Clinical motor and cognitive measures were assessed with Expanded Disability Status Scale (EDSS), Nine Hole Peg Test (NHPT), Timed 25-Foot Walk (T25FW), and Symbol Digit Modalities Test (SDMT).Results: pwMS showed strong and statistically significant correlations between gaze duration; number of fixations, saccade amplitude and motor disabilities and cognitive impairments as measured by EDSS, NHPT, T25FW, and SDMT.Conclusion: This study found significant correlations between eye movement behavior and motor and cognitive disability in pwMS. These findings suggest that eye movements have the potential to be used as a surrogate biomarker in MS progression.","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"10 2","pages":"20552173241255008"},"PeriodicalIF":2.8,"publicationDate":"2024-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11138185/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141179380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term efficacy and safety of rituximab in the treatment of neuromyelitis Optica Spectrum disorder. 利妥昔单抗治疗神经脊髓炎谱系障碍的长期疗效和安全性。

IF 2.8

Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2024-05-27 eCollection Date: 2024-04-01 DOI: 10.1177/20552173241257876

Michael T G Hayes, Robert J Adam, Pamela A McCombe, Michael Walsh, Stefan Blum

{"title":"Long-term efficacy and safety of rituximab in the treatment of neuromyelitis Optica Spectrum disorder.","authors":"Michael T G Hayes, Robert J Adam, Pamela A McCombe, Michael Walsh, Stefan Blum","doi":"10.1177/20552173241257876","DOIUrl":"10.1177/20552173241257876","url":null,"abstract":"Background: Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, autoimmune, inflammatory astrocytopathy. Rituximab for B-cell suppression is a common treatment for NMOSD; however, large-scale randomised controlled trials are lacking.Objective: Evaluate long-term efficacy and safety of rituximab for NMOSD.Methods: Retrospective observational study of patients with NMOSD treated with rituximab. Annualised relapse rates (ARRs) before and during rituximab treatment were evaluated; Modified Rankin Scores (mRS) were measured as a marker of disability.Results: In total, 37 patients were included: 27 aquaporin-4-IgG-seropositive and 10 seronegative NMOSD. The predominant rituximab dosing regimen was an initial 1000 mg, split over two 500 mg infusions, two weeks apart, followed by single 500 mg doses. Over a median follow-up of 54 months, ARR for the whole cohort was 0.136 (95% CI 0.088-0.201), significantly lower than the pretreatment ARR of 0.366 (95% CI 0.271-0.483, p < 0.001). There was a significant reduction in ARR for the seropositive subgroup, but not seronegative. Significant improvement in mRS was seen post-treatment. Infections were reported in 32% of patients during follow-up; most were mild.Conclusion: Rituximab, at doses lower than traditionally used, may be an efficacious therapy for NMOSD, with a favourable safety profile.","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"10 2","pages":"20552173241257876"},"PeriodicalIF":2.8,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11131406/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141162109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A comparative study of fatigue and processing speed in patients with multiple sclerosis treated with natalizumab or rituximab. 多发性硬化症患者接受纳他珠单抗或利妥昔单抗治疗后疲劳程度和处理速度的比较研究。

IF 2.8

Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2024-05-26 eCollection Date: 2024-04-01 DOI: 10.1177/20552173241252566

Johan Hellgren, Maria Compagno Strandberg, Kristina Källén, Anders Svenningsson

{"title":"A comparative study of fatigue and processing speed in patients with multiple sclerosis treated with natalizumab or rituximab.","authors":"Johan Hellgren, Maria Compagno Strandberg, Kristina Källén, Anders Svenningsson","doi":"10.1177/20552173241252566","DOIUrl":"10.1177/20552173241252566","url":null,"abstract":"Background: Fatigue is the most debilitating symptom in patients with multiple sclerosis (MS). Natalizumab and rituximab are the most used MS disease modifying therapies in Sweden, but comparative data on the effect on fatigue is sparse.Objective: Primary objective was to compare fatigue levels between patients on natalizumab and rituximab. As secondary objective, we assessed processing speed, an attention domain quality, between treatment groups.Method: In this Swedish multicentre cross-sectional study, patients with relapsing-remitting MS and >24 months treatment duration were identified in the Swedish MS-registry. Fatigue was assessed using the Fatigue Scale for Motor and Cognitive functions (FSMC) and processing speed using Symbol Digit Modalities Test (SDMT).Results: 128 patients were enrolled (natalizumab: 56, rituximab: 72). No significant differences in FSMC were found when adjusting for potential confounders (p = 0.936), with age having the biggest impact, correlating with increased fatigue. Individuals on natalizumab performed significantly better on SDMT at cross-section (natalizumab 64.7, rituximab 56.2; p = 0.003), with an improvement from treatment initiation, compared to rituximab (change: natalizumab 8.9, rituximab -1.0; p = 0.002).Conclusion: We found no difference in fatigue levels between natalizumab and rituximab cohorts. Patients treated with natalizumab showed significantly better results on SDMT than patients on rituximab.","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"10 2","pages":"20552173241252566"},"PeriodicalIF":2.8,"publicationDate":"2024-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11131408/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141162106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBase. 富马酸二甲酯与非特异性免疫抑制剂的疗效比较：来自 MSBase 的真实世界证据。

IF 2.8

Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2024-05-25 eCollection Date: 2024-04-01 DOI: 10.1177/20552173241247182

Tim Spelman, Sara Eichau, Raed Alroughani, Serkan Ozakbas, Samia J Khoury, Francesco Patti, Eva Kubala Havrdova, Cavit Boz, Murat Terzi, Jens Kuhle, Pierre Grammond, Jeanette Lechner-Scott, Orla Gray, Maria Pia Amato, Guy Laureys, Vahid Shaygannejad, Robert Hyde, Haijue Wang, Ivan Bozin, Nicholas Belviso, Chao Quan, Feng Zeng, Anneke van der Walt, Helmut Butzkueven

{"title":"Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBase.","authors":"Tim Spelman, Sara Eichau, Raed Alroughani, Serkan Ozakbas, Samia J Khoury, Francesco Patti, Eva Kubala Havrdova, Cavit Boz, Murat Terzi, Jens Kuhle, Pierre Grammond, Jeanette Lechner-Scott, Orla Gray, Maria Pia Amato, Guy Laureys, Vahid Shaygannejad, Robert Hyde, Haijue Wang, Ivan Bozin, Nicholas Belviso, Chao Quan, Feng Zeng, Anneke van der Walt, Helmut Butzkueven","doi":"10.1177/20552173241247182","DOIUrl":"10.1177/20552173241247182","url":null,"abstract":"Background: The use of non-specific immunosuppressants (NSIS) to treat multiple sclerosis (MS) remains prevalent in certain geographies despite safety concerns, likely due to resource limitations.Objective: To use MSBase registry data to compare real-world outcomes in adults with relapsing-remitting MS (RRMS) treated with dimethyl fumarate (DMF) or NSIS (azathioprine, cyclosporine, cyclophosphamide, methotrexate, mitoxantrone or mycophenolate mofetil) between January 1, 2014 and April 1, 2022.Methods: Treatment outcomes were compared using inverse probability of treatment weighting (IPTW) Cox regression. Outcomes were annualized relapse rates (ARRs), time to discontinuation, time to first relapse (TTFR) and time to 24-week confirmed disability progression (CDP) or 24-week confirmed disability improvement (CDI; in patients with baseline Expanded Disability Status Scale [EDSS] score ≥2).Results: After IPTW, ARR was similar for DMF (0.13) and NSIS (0.16; p = 0.29). There was no difference in TTFR between cohorts (hazard ratio [HR]: 0.98; p = 0.84). The DMF cohort experienced longer times to discontinuation (HR: 0.75; p = 0.001) and CDP (HR: 0.53; p = 0.001), and shorter time to CDI (HR: 1.99; p < 0.008), versus the NSIS cohort.Conclusion: This analysis supports the use of DMF to treat patients with relapsing forms of MS, and may have implications for MS practices in countries where NSIS are commonly used to treat RRMS.","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"10 2","pages":"20552173241247182"},"PeriodicalIF":2.8,"publicationDate":"2024-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11128181/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141154325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in a real-world setting: Final results from the Plegridy Observational Program. 在真实世界环境中，peginterferon beta-1a 治疗复发性多发性硬化症的安全性和临床有效性：Plegridy 观察项目的最终结果。

IF 2.8

Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2024-05-23 eCollection Date: 2024-04-01 DOI: 10.1177/20552173241238632

Marco Salvetti, Sibyl Wray, Gereon Nelles, Nicholas Belviso, Achint Kumar, Thijs Koster, Wanda Castro-Borrero, Megan Vignos

{"title":"Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in a real-world setting: Final results from the Plegridy Observational Program.","authors":"Marco Salvetti, Sibyl Wray, Gereon Nelles, Nicholas Belviso, Achint Kumar, Thijs Koster, Wanda Castro-Borrero, Megan Vignos","doi":"10.1177/20552173241238632","DOIUrl":"10.1177/20552173241238632","url":null,"abstract":"Background: Interferon beta-1a remains an important treatment option for multiple sclerosis, particularly when safety or tolerability concerns may outweigh the benefits of higher-efficacy disease-modifying therapies. The five-year phase 4 Plegridy Observational Program (POP) study (NCT02230969) collected data on real-world safety and effectiveness of Plegridy® (peginterferon beta-1a) treatment in patients with relapsing multiple sclerosis.Objective: To explore the real-world safety and effectiveness of peginterferon beta-1a in patients with relapsing multiple sclerosis, including factors influencing treatment discontinuation.Methods: Data were collected prospectively from patients ≥ 18 years old with relapsing multiple sclerosis for overall population analysis and for subpopulations including newly/previously diagnosed patients, age, and experience with peginterferon beta-1a. Outcome measures included annualized relapse rates, adverse events, and predictors of time to treatment discontinuation.Results: Mean (SD) treatment duration in the overall population (N = 1172) was 896.0 (733.15) days. Incidence of adverse events was higher in new than experienced users (79.4% vs. 57.0%). New users were more likely than experienced users to discontinue (hazard ratio = 1.60; P < 0.0001). The adjusted annualized relapse rate was 0.09, and at the end of 5 years, 77.1% of patients were relapse-free.Conclusions: Peginterferon beta-1a is an effective therapy for managing relapsing multiple sclerosis. The identification of predictors of discontinuation can help inform strategies to enhance treatment persistence.","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"10 2","pages":"20552173241238632"},"PeriodicalIF":2.8,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11113050/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141088124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Low-intensity repetitive transcranial magnetic stimulation is safe and well tolerated by people living with MS - outcomes of the phase I randomised controlled trial (TAURUS). 低强度重复经颅磁刺激对多发性硬化症患者安全且耐受性良好--第一阶段随机对照试验（TAURUS）的结果。

IF 2.8

Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2024-05-15 eCollection Date: 2024-04-01 DOI: 10.1177/20552173241252571

Phuong Tram Nguyen, Amin Zarghami, Kalina Makowiecki, Natasha Stevens, Chigozie Ezegbe, Kain Kyle, Chenyu Wang, Linda Ly, Katie De La Rue, Mark R Hinder, Lewis Johnson, Jennifer Rodger, Samantha Cooper, Carlie L Cullen, Michael Barnett, Kaylene M Young, Bruce V Taylor

{"title":"Low-intensity repetitive transcranial magnetic stimulation is safe and well tolerated by people living with MS - outcomes of the phase I randomised controlled trial (TAURUS).","authors":"Phuong Tram Nguyen, Amin Zarghami, Kalina Makowiecki, Natasha Stevens, Chigozie Ezegbe, Kain Kyle, Chenyu Wang, Linda Ly, Katie De La Rue, Mark R Hinder, Lewis Johnson, Jennifer Rodger, Samantha Cooper, Carlie L Cullen, Michael Barnett, Kaylene M Young, Bruce V Taylor","doi":"10.1177/20552173241252571","DOIUrl":"https://doi.org/10.1177/20552173241252571","url":null,"abstract":"Background: Low-intensity repetitive transcranial magnetic stimulation (rTMS), delivered as a daily intermittent theta burst stimulation (iTBS) for four consecutive weeks, increased the number of new oligodendrocytes in the adult mouse brain. Therefore, rTMS holds potential as a remyelinating intervention for people with multiple sclerosis (MS).Objective: Primarily to determine the safety and tolerability of our rTMS protocol in people with MS. Secondary objectives include feasibility, blinding and an exploration of changes in magnetic resonance imaging (MRI) metrics, patient-reported outcome measures (PROMs) and cognitive or motor performance.Methods: A randomised (2:1), placebo controlled, single blind, parallel group, phase 1 trial of 20 rTMS sessions (600 iTBS pulses per hemisphere; 25% maximum stimulator output), delivered over 4-5 weeks. Twenty participants were randomly assigned to 'sham' (n = 7) or active rTMS (n = 13), with the coil positioned at 90° or 0°, respectively.Results: Five adverse events (AEs) including one serious AE reported. None were related to treatment. Protocol compliance was high (85%) and blinding successful. Within participant MRI metrics, PROMs and cognitive or motor performance were unchanged over time.Conclusion: Twenty sessions of rTMS is safe and well tolerated in a small group of people with MS. The study protocol and procedures are feasible. Improvement of sham is warranted before further investigating safety and efficacy.","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"10 2","pages":"20552173241252571"},"PeriodicalIF":2.8,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11097717/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140958537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical outcomes after use of checkpoint inhibitor immunotherapies in people with multiple sclerosis. 多发性硬化症患者使用检查点抑制剂免疫疗法后的临床疗效。

IF 2.8

Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2024-05-07 eCollection Date: 2024-04-01 DOI: 10.1177/20552173241252563

Alyssa N Nylander, William Rowles, Shane Poole, Riley Bove

{"title":"Clinical outcomes after use of checkpoint inhibitor immunotherapies in people with multiple sclerosis.","authors":"Alyssa N Nylander, William Rowles, Shane Poole, Riley Bove","doi":"10.1177/20552173241252563","DOIUrl":"10.1177/20552173241252563","url":null,"abstract":"Background: Immune checkpoint inhibitors (ICIs) represent a novel class of agents approved for the treatment of several cancers and progressive multifocal leukoencephalopathy (PML). However, due to the risk of autoimmune side effects, their use in people with autoimmune diseases such as multiple sclerosis (MS) has been limited.Objective: To characterize outcomes in a cohort of adults with MS who received ICIs.Methods: A single-center retrospective review of medical record data was performed for people with MS treated with ICIs.Results: Seven people with MS were identified, with a mean (SD) age at ICI use of 55.4 (13.7) years and a mean MS duration of 18.2 (12.2) years. Six were treated for cancer; 1 was treated for PML. After mean (SD) follow-up of 1.76 (2.15) years after ICI, outcomes are: no evidence of disease (2), residual metastatic disease (1), death due to cancer (1), death due to PML (1), and lost to follow-up (2). Notably, 0 out of 7 patients experienced an MS relapse; two out of six had new asymptomatic demyelinating magnetic resonance imaging lesions. In the three patients with expanded disability status scale (EDSS) scores at baseline and follow-up, EDSS remained stable (mean delta 0.13).Conclusion: In this cohort, no people with MS experienced clinical relapses and one-third experienced asymptomatic radiological activity following ICI treatment.","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"10 2","pages":"20552173241252563"},"PeriodicalIF":2.8,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11078085/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140892048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The patient-reported wearing-off phenomenon with monoclonal antibody treatments for multiple sclerosis. 单克隆抗体治疗多发性硬化症的患者报告磨损现象。

IF 2.8

Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2024-05-06 eCollection Date: 2024-04-01 DOI: 10.1177/20552173241251707

Lindsey M Marian, Kathleen A Harris, Devon S Conway

{"title":"The patient-reported wearing-off phenomenon with monoclonal antibody treatments for multiple sclerosis.","authors":"Lindsey M Marian, Kathleen A Harris, Devon S Conway","doi":"10.1177/20552173241251707","DOIUrl":"10.1177/20552173241251707","url":null,"abstract":"Background: Many patients report a wearing-off phenomenon with monoclonal antibody treatment for multiple sclerosis in which perceived benefits wear off before the next dose is due.Objectives: To determine prevalence of the wearing-off effect, symptoms experienced, impact on treatment satisfaction, and associated patient characteristics.Methods: Patients receiving natalizumab, ocrelizumab, ofatumumab, or rituximab at a tertiary multiple sclerosis center were invited to take an online survey interrogating their monoclonal antibody experience. Additional history and patient characteristic data were collected. Logistic regression was used to determine if patient characteristics predicted the wearing-off effect and linear regression to evaluate the impact of the wearing-off effect on treatment satisfaction. The models were adjusted for age, disease duration, race, sex, body mass index, education, and depression as measured by the Patient Health Questionnaire-9.Results: We received 258 qualifying responses and 141 (54.7%) patients reported the wearing-off phenomenon. The most common symptom was fatigue (47.7%). Higher Patient Health Questionnaire-9 scores were significantly associated with the wearing-off phenomenon (OR = 1.02, p = 0.005). The wearing-off effect (β = -0.52, p = 0.04) and higher Patient Health Questionnaire-9 (β = -0.09, p < 0.01) scores were associated with significantly reduced treatment satisfaction.Conclusion: The wearing-off phenomenon is common, associated with depression, and reduces treatment satisfaction. Research addressing mitigation strategies is needed.","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"10 2","pages":"20552173241251707"},"PeriodicalIF":2.8,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11075606/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140876867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High-resolution diffusion tensor imaging of the fornix predicts memory function in multiple sclerosis. 穹窿的高分辨率弥散张量成像可预测多发性硬化症患者的记忆功能。

IF 2.8

Multiple Sclerosis Journal - Experimental, Translational and Clinical Pub Date : 2024-05-06 eCollection Date: 2024-04-01 DOI: 10.1177/20552173241240937

Katherine A Koenig, Ken E Sakaie, Daniel Ontaneda, Kedar R Mahajan, Se-Hong Oh, Kunio Nakamura, Stephen E Jones, Stephen M Rao, Mark J Lowe

{"title":"High-resolution diffusion tensor imaging of the fornix predicts memory function in multiple sclerosis.","authors":"Katherine A Koenig, Ken E Sakaie, Daniel Ontaneda, Kedar R Mahajan, Se-Hong Oh, Kunio Nakamura, Stephen E Jones, Stephen M Rao, Mark J Lowe","doi":"10.1177/20552173241240937","DOIUrl":"10.1177/20552173241240937","url":null,"abstract":"Background: Cognitive dysfunction is a known symptom of multiple sclerosis (MS), with memory recognized as a frequently impacted domain. Here, we used high-resolution MRI at 7 tesla to build on cross-sectional work by evaluating the longitudinal relationship of diffusion tensor imaging (DTI) measures of the fornix to episodic memory performance.Methods: A sample of 80 people with multiple sclerosis (mean age 51.9 ± 8.1 years; 24% male) underwent baseline clinical evaluation, neuropsychological assessment, and MRI. Sixty-four participants had follow-up neuropsychological testing after 1-2 years. Linear regression was used to assess the relationship of baseline imaging measures to follow-up episodic memory performance, measured using the Selective Reminding Test and Brief Visuospatial Memory Test. A reduced prediction model included cognitive function at baseline, age, sex, and disease course.Results: Radial (β = -0.222, p < 0.026; likelihood ratio test (LRT) p < 0.018), axial (β = -0.270, p < 0.005; LRT p < 0.003), and mean (β = -0.242, p < 0.0139; LRT p < 0.009) diffusivity of the fornix significantly added to the model, with follow-up analysis indicating that a longer prediction interval may increase accuracy.Conclusion: These results suggest that fornix DTI has predictive value specific to memory function in MS and warrants additional investigation in the drive to develop predictors of disease progression.","PeriodicalId":18961,"journal":{"name":"Multiple Sclerosis Journal - Experimental, Translational and Clinical","volume":"10 2","pages":"20552173241240937"},"PeriodicalIF":2.8,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11075608/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140876866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0